Keyphrases
Phase II Trial
100%
Neoadjuvant
100%
Resectable Lung Cancer
100%
Atezolizumab
100%
Peripheral Blood
60%
Immune Parameters
40%
Confidence Interval
20%
Tumor
20%
Adverse Events
20%
Monotherapy
20%
Survival Rate
20%
Pathological Response
20%
Two-dose
20%
Large Cohort
20%
Phase II Study
20%
New Therapeutic Approaches
20%
Malignant Cells
20%
Non-small Cell Lung Cancer (NSCLC)
20%
Innate Immune Cells
20%
Tumor Microenvironment
20%
Patient Selection
20%
Point Analysis
20%
3-year Survival
20%
Immunophenotyping
20%
Non-randomized Trial
20%
Immune Toxicity
20%
Safety Signal
20%
Procedural Pain
20%
Major Pathological Response
20%
Medicine and Dentistry
Arm
100%
Non Small Cell Lung Cancer
100%
Phase II Trials
100%
Atezolizumab
100%
Immunocompetent Cell
75%
Neoplasm
25%
Adverse Event
25%
Monotherapy
25%
Survival Rate
25%
Epidermal Growth Factor Receptor
25%
Tumor Microenvironment
25%
Patient Selection
25%
Immunophenotyping
25%
Procedural Pain
25%
Immunology and Microbiology
Arm
100%
Atezolizumab
100%
Immunocompetent Cell
50%
Survival Rate
25%
Innate Immune Cell
25%